Role of non-coding RNAs in neuroblastoma.
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
02
11
2022
accepted:
04
05
2023
revised:
25
03
2023
medline:
18
9
2023
pubmed:
23
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
Neuroblastoma is known as the most prevalent extracranial malignancy in childhood with a neural crest origin. It has been widely accepted that non-coding RNAs (ncRNAs) play important roles in many types of cancer, including glioma and gastrointestinal cancers. They may regulate the cancer gene network. According to recent sequencing and profiling studies, ncRNAs genes are deregulated in human cancers via deletion, amplification, abnormal epigenetic, or transcriptional regulation. Disturbances in the expression of ncRNAs may act either as oncogenes or as anti-tumor suppressor genes, and can lead to the induction of cancer hallmarks. ncRNAs can be secreted from tumor cells inside exosomes, where they can be transferred to other cells to affect their function. However, these topics still need more study to clarify their exact roles, so the present review addresses different roles and functions of ncRNAs in neuroblastoma.
Identifiants
pubmed: 37217790
doi: 10.1038/s41417-023-00623-0
pii: 10.1038/s41417-023-00623-0
doi:
Substances chimiques
RNA, Untranslated
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1190-1208Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Gao T, Wang M, Xu L, Wen T, Liu J, An G. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer. J Cancer Res Clin Oncol. 2016;142:2131–40.
pubmed: 27520310
doi: 10.1007/s00432-016-2218-0
Luksch R, Podda M, Gandola L, Polastri D, Piva L, Castellani R, et al. Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment. Br J Cancer. 2005;92:1984–8.
pubmed: 15900298
pmcid: 2361794
doi: 10.1038/sj.bjc.6602615
Luksch R, Castellani MR, Collini P, De Bernardi B, Conte M, Gambini C, et al. Neuroblastoma (Peripheral neuroblastic tumours). Crit Rev Oncol Hematol. 2016;107:163–81.
pubmed: 27823645
doi: 10.1016/j.critrevonc.2016.10.001
Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–16.
pubmed: 12612655
doi: 10.1038/nrc1014
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.
pubmed: 8336186
doi: 10.1200/JCO.1993.11.8.1466
Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol. 1995;24:215–21.
pubmed: 7700165
doi: 10.1002/mpo.2950240402
Caron H, van Sluis P, de Kraker J, Bökkerink J, Egeler M, Laureys G, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N. Engl J Med. 1996;334:225–30.
pubmed: 8531999
doi: 10.1056/NEJM199601253340404
Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5−a population-based study. Lancet Oncol. 2014;15:35–47.
pubmed: 24314616
doi: 10.1016/S1470-2045(13)70548-5
Trama A, Botta L, Foschi R, Ferrari A, Stiller C, Desandes E, et al. Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5. Lancet Oncol. 2016;17:896–906.
pubmed: 27237614
doi: 10.1016/S1470-2045(16)00162-5
Khani P, Nasri F, Khani Chamani F, Saeidi F, Sadri Nahand J, Tabibkhooei A, et al. Genetic and epigenetic contribution to astrocytic gliomas pathogenesis. J Neurochem. 2019;148:188–203.
pubmed: 30347482
doi: 10.1111/jnc.14616
Mirzaei H, Hamblin MR. Regulation of glycolysis by non-coding RNAs in cancer: switching on the Warburg effect. Mol Ther Oncolytics. 2020;19:218–39.
pubmed: 33251334
pmcid: 7666327
doi: 10.1016/j.omto.2020.10.003
Bejerano G, Pheasant M, Makunin I, Stephen S, Kent WJ, Mattick JS, et al. Ultraconserved elements in the human genome. Science. 2004;304:1321–5.
pubmed: 15131266
doi: 10.1126/science.1098119
Johnsson P, Lipovich L, Grandér D, Morris KV. Evolutionary conservation of long non-coding RNAs; sequence, structure, function. Biochim Biophys Acta. 2014;1840:1063–71.
pubmed: 24184936
doi: 10.1016/j.bbagen.2013.10.035
Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature. 2012;489:101–8.
pubmed: 22955620
pmcid: 3684276
doi: 10.1038/nature11233
ENCODE Project Consortium. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science 2004; 306:636-40.
Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012;149:515–24.
pubmed: 22541426
pmcid: 3351105
doi: 10.1016/j.cell.2012.04.005
Yamamura S, Imai-Sumida M, Tanaka Y, Dahiya R. Interaction and cross-talk between non-coding RNAs. Cell Mol Life Sci. 2018;75:467–84.
pubmed: 28840253
doi: 10.1007/s00018-017-2626-6
Barabási AL, Oltvai ZN. Network biology: understanding the cell’s functional organization. Nat Rev Genet. 2004;5:101–13.
pubmed: 14735121
doi: 10.1038/nrg1272
Alon U. Network motifs: theory and experimental approaches. Nat Rev Genet. 2007;8:450–61.
pubmed: 17510665
doi: 10.1038/nrg2102
Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11:849–64.
pubmed: 22113163
pmcid: 4314215
doi: 10.1038/nrc3166
He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–31.
pubmed: 15211354
doi: 10.1038/nrg1379
Kim VN. Small RNAs: classification, biogenesis, and function. Mol Cells. 2005;19:1–15.
pubmed: 15750334
Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008;30:460–71.
pubmed: 18498749
doi: 10.1016/j.molcel.2008.05.001
Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. miR-148 targets human DNMT3b protein coding region. Rna. 2008;14:872–7.
pubmed: 18367714
pmcid: 2327368
doi: 10.1261/rna.972008
Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature. 2008;455:64–71.
pubmed: 18668037
pmcid: 2745094
doi: 10.1038/nature07242
Breving K, Esquela-Kerscher A. The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol. 2010;42:1316–29.
pubmed: 19800023
doi: 10.1016/j.biocel.2009.09.016
Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Ann Rev Med. 2009;60:167–79.
pubmed: 19630570
doi: 10.1146/annurev.med.59.053006.104707
Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007;318:1931–4.
pubmed: 18048652
doi: 10.1126/science.1149460
Calin GA. MicroRNAs and cancer: what we know and what we still have to learn. Genome Med. 2009;1:78.
pubmed: 19691821
pmcid: 2768964
doi: 10.1186/gm78
Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, et al. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS ONE. 2009;4:e7850.
pubmed: 19924232
pmcid: 2773120
doi: 10.1371/journal.pone.0007850
Wang S, Olson EN. AngiomiRs−key regulators of angiogenesis. Curr Opin Genet Dev. 2009;19:205–11.
pubmed: 19446450
pmcid: 2696563
doi: 10.1016/j.gde.2009.04.002
Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007;67:976–83.
pubmed: 17283129
doi: 10.1158/0008-5472.CAN-06-3667
Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, Vermeulen J, et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene. 2010;29:1394–404.
pubmed: 19946337
doi: 10.1038/onc.2009.429
Tivnan A, Foley NH, Tracey L, Davidoff AM, Stallings RL. MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma. Anticancer Res. 2010;30:4391–5.
pubmed: 21115884
pmcid: 5030819
Bray I, Tivnan A, Bryan K, Foley NH, Watters KM, Tracey L, et al. MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett. 2011;303:56–64.
pubmed: 21310526
pmcid: 3057396
doi: 10.1016/j.canlet.2011.01.016
Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE. 2008;3:e2236.
pubmed: 18493594
pmcid: 2375057
doi: 10.1371/journal.pone.0002236
Schulte JH, Schowe B, Mestdagh P, Kaderali L, Kalaghatgi P, Schlierf S, et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer. 2010;127:2374–85.
pubmed: 20473924
doi: 10.1002/ijc.25436
Tivnan A, Tracey L, Buckley PG, Alcock LC, Davidoff AM, Stallings RL. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer. 2011;11:33.
pubmed: 21266077
pmcid: 3038978
doi: 10.1186/1471-2407-11-33
Lu Y, Maruyama J, Kuwata K, Fukuda H, Iwasa H, Arimoto-Matsuzaki K, et al. Doublecortin-like kinase 1 compromises DNA repair and induces chromosomal instability. Biochem Biophys Rep. 2018;16:130–7.
pubmed: 30417131
pmcid: 6216093
Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007;26:5017–22.
pubmed: 17297439
doi: 10.1038/sj.onc.1210293
Chandrakesan P, May R, Weygant N, Qu D, Berry WL, Sureban SM, et al. Intestinal tuft cells regulate the ATM mediated DNA Damage response via Dclk1 dependent mechanism for crypt restitution following radiation injury. Sci Rep. 2016;6:37667.
pubmed: 27876863
pmcid: 5120335
doi: 10.1038/srep37667
Chandrakesan P, Yao J, Qu D, May R, Weygant N, Ge Y, et al. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells. Mol Cancer. 2017;16:30.
pubmed: 28148261
pmcid: 5286867
doi: 10.1186/s12943-017-0594-y
Sureban SM, May R, Qu D, Weygant N, Chandrakesan P, Ali N, et al. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PLoS ONE. 2013;8:e73940.
pubmed: 24040120
pmcid: 3767662
doi: 10.1371/journal.pone.0073940
Suehiro Y, Takemoto Y, Nishimoto A, Ueno K, Shirasawa B, Tanaka T, et al. Dclk1 inhibition cancels 5-FU-induced cell-cycle arrest and decreases cell survival in colorectal cancer. Anticancer Res. 2018;38:6225–30.
pubmed: 30396941
doi: 10.21873/anticanres.12977
Li J, Wang Y, Ge J, Li W, Yin L, Zhao Z, et al. Doublecortin-Like kinase 1 (DCLK1) regulates B cell-specific moloney murine leukemia virus insertion site 1 (Bmi-1) and is associated with metastasis and prognosis in pancreatic cancer. Cell Physiol Biochem. 2018;51:262–77.
pubmed: 30453285
doi: 10.1159/000495228
Mallick S, D’Mello SR. JAZ (Znf346), a SIRT1-interacting protein, protects neurons by stimulating p21 (WAF/CIP1) protein expression. J Biol Chem. 2014;289:35409–20.
pubmed: 25331946
pmcid: 4271226
doi: 10.1074/jbc.M114.597575
Wu T, Lin Y, Xie Z. MicroRNA-1247 inhibits cell proliferation by directly targeting ZNF346 in childhood neuroblastoma. Biol Res. 2018;51:13.
pubmed: 29793538
pmcid: 5966945
doi: 10.1186/s40659-018-0162-y
Wei Q, Guo Z, Chen D, Jia X. MiR-542-3p Suppresses Neuroblastoma Cell Proliferation and Invasion by Downregulation of KDM1A and ZNF346. Open Life Sci. 2020;15:173–84.
pubmed: 33987474
pmcid: 8114778
doi: 10.1515/biol-2020-0018
Aguilar-Cuenca R, Juanes-García A, Vicente-Manzanares M. Myosin II in mechanotransduction: master and commander of cell migration, morphogenesis, and cancer. Cell Mol Life Sci. 2014;71:479–92.
pubmed: 23934154
doi: 10.1007/s00018-013-1439-5
Liang S, He L, Zhao X, Miao Y, Gu Y, Guo C, et al. MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS ONE. 2011;6:e18409.
pubmed: 21533124
pmcid: 3078939
doi: 10.1371/journal.pone.0018409
Murthy K, Wadsworth P. Myosin-II-dependent localization and dynamics of F-actin during cytokinesis. Curr Biol. 2005;15:724–31.
pubmed: 15854904
doi: 10.1016/j.cub.2005.02.055
Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol. 2009;10:778–90.
pubmed: 19851336
pmcid: 2834236
doi: 10.1038/nrm2786
Chao C, Lotz MM, Clarke AC, Mercurio AM. A function for the integrin alpha6beta4 in the invasive properties of colorectal carcinoma cells. Cancer Res. 1996;56:4811–9.
pubmed: 8841003
Lu S, Simin K, Khan A, Mercurio AM. Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin Cancer Res. 2008;14:1050–8.
pubmed: 18281537
doi: 10.1158/1078-0432.CCR-07-4116
Liu W, Wang S, Sun Q, Yang Z, Liu M, Tang H. DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-κB pathway in colorectal cancer. Int J Cancer. 2018;142:2068–79.
pubmed: 29277893
doi: 10.1002/ijc.31232
Karytinos A, Forneris F, Profumo A, Ciossani G, Battaglioli E, Binda C, et al. A novel mammalian flavin-dependent histone demethylase. J Biol Chem. 2009;284:17775–82.
pubmed: 19407342
pmcid: 2719416
doi: 10.1074/jbc.M109.003087
Wan MF, Yang N, Qu NY, Pan YY, Shan YQ, Li P. MiR-424 suppressed viability and invasion by targeting to the DCLK1 in neuroblastoma. Eur Rev Med Pharm Sci. 2020;24:5526–33.
Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol. 2012;43:1300–7.
pubmed: 22245111
doi: 10.1016/j.humpath.2011.10.010
Ismail T, Lee HK, Kim C, Kwon T, Park TJ, Lee HS. KDM1A microenvironment, its oncogenic potential, and therapeutic significance. Epigenet Chromatin. 2018;11:33.
doi: 10.1186/s13072-018-0203-3
Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell. 2005;19:857–64.
pubmed: 16140033
doi: 10.1016/j.molcel.2005.08.027
Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006;66:11341–7.
pubmed: 17145880
doi: 10.1158/0008-5472.CAN-06-1570
Magerl C, Ellinger J, Braunschweig T, Kremmer E, Koch LK, Höller T, et al. H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Hum Pathol. 2010;41:181–9.
pubmed: 19896696
doi: 10.1016/j.humpath.2009.08.007
Kong L, Zhang P, Li W, Yang Y, Tian Y, Wang X, et al. KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells. Oncotarget. 2016;7:27959–74.
pubmed: 27058897
pmcid: 5053702
doi: 10.18632/oncotarget.8563
Sareddy GR, Viswanadhapalli S, Surapaneni P, Suzuki T, Brenner A, Vadlamudi RK. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway. Oncogene. 2017;36:2423–34.
pubmed: 27893719
doi: 10.1038/onc.2016.395
O’Reilly JA, Fitzgerald J, Fitzgerald S, Kenny D, Kay EW, O’Kennedy R, et al. Diagnostic potential of zinc finger protein-specific autoantibodies and associated linear B-cell epitopes in colorectal cancer. PLoS ONE. 2015;10:e0123469.
pubmed: 25875936
pmcid: 4395473
doi: 10.1371/journal.pone.0123469
Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol. 2018;36:3007–14.
pubmed: 29733771
doi: 10.1200/JCO.2018.78.2292
Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, et al. Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Disco. 2016;6:492–500.
doi: 10.1158/2159-8290.CD-15-1335
Liu C, Gen Y, Tanimoto K, Muramatsu T, Inoue J, Inazawa J. Concurrent targeting of MAP3K3 and BRD4 by miR-3140-3p overcomes acquired resistance to BET inhibitors in neuroblastoma cells. Mol Ther Nucleic Acids. 2021;25:83–92.
pubmed: 34258104
pmcid: 8253920
doi: 10.1016/j.omtn.2021.05.001
Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol. 2000;12:85–98.
pubmed: 10723801
doi: 10.1006/smim.2000.0210
Pacifico F, Leonardi A. NF-kappaB in solid tumors. Biochem Pharm. 2006;72:1142–52.
pubmed: 16956585
doi: 10.1016/j.bcp.2006.07.032
Xiong S, Wang Y, Li H, Zhang X. Low dose of bisphenol A activates NF-κB/IL-6 signals to increase malignancy of neuroblastoma cells. Cell Mol Neurobiol. 2017;37:1095–103.
pubmed: 27866306
doi: 10.1007/s10571-016-0443-3
Häcker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE. 2006;2006:re13.
pubmed: 17047224
doi: 10.1126/stke.3572006re13
Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18:2195–224.
pubmed: 15371334
doi: 10.1101/gad.1228704
Kaisho T, Tanaka T. Turning NF-kappaB and IRFs on and off in DC. Trends Immunol. 2008;29:329–36.
pubmed: 18534908
doi: 10.1016/j.it.2008.03.005
Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6.
pubmed: 16724054
doi: 10.1038/nature04870
Yu J, Wang L, Zhang T, Shen H, Dong W, Ni Y, et al. Co-expression of β-arrestin1 and NF-кB is associated with cancer progression and poor prognosis in lung adenocarcinoma. Tumour Biol. 2015;36:6551–8.
pubmed: 25820700
doi: 10.1007/s13277-015-3349-7
Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death−a new approach to cancer therapy. J Clin Invest. 2005;115:2625–32.
pubmed: 16200195
pmcid: 1236696
doi: 10.1172/JCI26322
Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. 1998;1:543–51.
pubmed: 9660938
doi: 10.1016/S1097-2765(00)80054-4
Nolan JC, Salvucci M, Carberry S, Barat A, Segura MF, Fenn J, et al. A context-dependent role for MiR-124-3p on cell phenotype, viability and chemosensitivity in neuroblastoma in vitro. Front Cell Dev Biol. 2020;8:559553.
pubmed: 33330445
pmcid: 7714770
doi: 10.3389/fcell.2020.559553
Sutoh Yoneyama M, Hatakeyama S, Habuchi T, Inoue T, Nakamura T, Funyu T, et al. Vimentin intermediate filament and plectin provide a scaffold for invadopodia, facilitating cancer cell invasion and extravasation for metastasis. Eur J Cell Biol. 2014;93:157–69.
pubmed: 24810881
doi: 10.1016/j.ejcb.2014.03.002
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14:999–1008.
pubmed: 23890779
pmcid: 3963485
doi: 10.1016/S1470-2045(13)70309-7
Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci USA. 2012;109:9545–50.
pubmed: 22623531
pmcid: 3386069
doi: 10.1073/pnas.1121119109
Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159:1126–39.
pubmed: 25416950
pmcid: 4243043
doi: 10.1016/j.cell.2014.10.024
Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer. 2012;12:465–77.
pubmed: 22722403
pmcid: 3934568
doi: 10.1038/nrc3256
Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, et al. Targeting MYCN-driven transcription By BET-bromodomain inhibition. Clin Cancer Res. 2016;22:2470–81.
pubmed: 26631615
doi: 10.1158/1078-0432.CCR-15-1449
Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Disco. 2013;3:308–23.
doi: 10.1158/2159-8290.CD-12-0418
Zimmerman MW, Liu Y, He S, Durbin AD, Abraham BJ, Easton J, et al. MYC drives a subset of high-risk pediatric neuroblastomas and is activated through mechanisms including enhancer hijacking and focal enhancer amplification. Cancer Discov. 2018;8:320–35.
pubmed: 29284669
doi: 10.1158/2159-8290.CD-17-0993
Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 2000;1470:M55–62.
pubmed: 10722927
Maldonado MDM, Dharmawardhane S. Targeting Rac and Cdc42 GTPases in Cancer. Cancer Res. 2018;78:3101–11.
pubmed: 29858187
doi: 10.1158/0008-5472.CAN-18-0619
Li X, Jiang M, Chen D, Xu B, Wang R, Chu Y, et al. miR-148b-3p inhibits gastric cancer metastasis by inhibiting the Dock6/Rac1/Cdc42 axis. J Exp Clin Cancer Res. 2018;37:71.
pubmed: 29587866
pmcid: 5872400
doi: 10.1186/s13046-018-0729-z
Meteoglu I, Erdogdu IH, Meydan N, Erkus M, Barutca S. NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin Cancer Res. 2008;27:53.
pubmed: 18928570
pmcid: 2577088
doi: 10.1186/1756-9966-27-53
Zhou X, Lu H, Li F, Hao X, Han L, Dong Q, et al. MicroRNA-429 inhibits neuroblastoma cell proliferation, migration and invasion via the NF-κB pathway. Cell Mol Biol Lett. 2020;25:5.
pubmed: 32082390
pmcid: 7020518
doi: 10.1186/s11658-020-0202-9
Shi C, Ren L, Sun C, Yu L, Bian X, Zhou X, et al. miR-29a/b/c function as invasion suppressors for gliomas by targeting CDC42 and predict the prognosis of patients. Br J Cancer. 2017;117:1036–47.
pubmed: 28787434
pmcid: 5625669
doi: 10.1038/bjc.2017.255
Li SH, Li JP, Chen L, Liu JL. miR-146a induces apoptosis in neuroblastoma cells by targeting BCL11A. Med Hypotheses. 2018;117:21–27.
pubmed: 30077189
doi: 10.1016/j.mehy.2018.05.019
Yang JY, Li Y, Wang Q, Zhou WJ, Yan YN, Wei WB. MicroRNA-145 suppresses uveal melanoma angiogenesis and growth by targeting neuroblastoma RAS viral oncogene homolog and vascular endothelial growth factor. Chin Med J (Engl). 2020;133:1922–9.
pubmed: 32826455
doi: 10.1097/CM9.0000000000000875
Chakrabarti M, Banik NL, Ray SK. miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma in vitro and in vivo. Exp Cell Res. 2013;319:1575–85.
pubmed: 23562653
pmcid: 3661724
doi: 10.1016/j.yexcr.2013.02.025
Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152:1298–307.
pubmed: 23498938
pmcid: 3651923
doi: 10.1016/j.cell.2013.02.012
Lee HS, Lee K, Jang HJ, Lee GK, Park JL, Kim SY, et al. Epigenetic silencing of the non-coding RNA nc886 provokes oncogenes during human esophageal tumorigenesis. Oncotarget. 2014;5:3472–81.
pubmed: 25004084
pmcid: 4116496
doi: 10.18632/oncotarget.1927
Wu Y, Liu H, Shi X, Yao Y, Yang W, Song Y. The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. Oncotarget. 2015;6:9160–72.
pubmed: 25863539
pmcid: 4496209
doi: 10.18632/oncotarget.3247
Mazar J, Zhao W, Khalil AM, Lee B, Shelley J, Govindarajan SS, et al. The functional characterization of long noncoding RNA SPRY4-IT1 in human melanoma cells. Oncotarget. 2014;5:8959–69.
pubmed: 25344859
pmcid: 4253410
doi: 10.18632/oncotarget.1863
Guo H, Zhang X, Dong R, Liu X, Li Y, Lu S, et al. Integrated analysis of long noncoding RNAs and mRNAs reveals their potential roles in the pathogenesis of uterine leiomyomas. Oncotarget. 2014;5:8625–36.
pubmed: 25268745
pmcid: 4226709
doi: 10.18632/oncotarget.2349
Xue Y, Ma G, Zhang Z, Hua Q, Chu H, Tong N, et al. A novel antisense long noncoding RNA regulates the expression of MDC1 in bladder cancer. Oncotarget. 2015;6:484–93.
pubmed: 25514464
doi: 10.18632/oncotarget.2861
Pandey GK, Kanduri C. Fighting neuroblastomas with NBAT1. Oncoscience. 2015;2:79–80.
pubmed: 25859549
pmcid: 4381699
doi: 10.18632/oncoscience.126
Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, et al. A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015;27:370–81.
pubmed: 25759022
doi: 10.1016/j.ccell.2015.02.004
Lee KS, Park JL, Lee K, Richardson LE, Johnson BH, Lee HS, et al. nc886, a non-coding RNA of anti-proliferative role, is suppressed by CpG DNA methylation in human gastric cancer. Oncotarget. 2014;5:3944–55.
pubmed: 25003254
pmcid: 4116533
doi: 10.18632/oncotarget.2047
Li H, Yu B, Li J, Su L, Yan M, Zhu Z, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014;5:2318–29.
pubmed: 24810858
pmcid: 4039165
doi: 10.18632/oncotarget.1913
Buechner J, Einvik C. N-myc and noncoding RNAs in neuroblastoma. Mol cancer Res. 2012;10:1243–53.
pubmed: 22936790
doi: 10.1158/1541-7786.MCR-12-0244
Whitehead J, Pandey GK, Kanduri C. Regulation of the mammalian epigenome by long noncoding RNAs. Biochim Biophys Acta. 2009;1790:936–47.
pubmed: 19015002
doi: 10.1016/j.bbagen.2008.10.007
Castelnuovo M, Massone S, Tasso R, Fiorino G, Gatti M, Robello M, et al. An Alu-like RNA promotes cell differentiation and reduces malignancy of human neuroblastoma cells. FASEB J. 2010;24:4033–46.
pubmed: 20581224
doi: 10.1096/fj.10-157032
Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M, et al. Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression. J Natl Cancer Inst. 2014;106:dju113.
pubmed: 24906397
doi: 10.1093/jnci/dju113
Wei W, Liu Y, Lu Y, Yang B, Tang L. LncRNA XIST Promotes Pancreatic Cancer Proliferation Through miR-133a/EGFR. J Cell Biochem. 2017;118:3349–58.
pubmed: 28295543
doi: 10.1002/jcb.25988
Chen DL, Chen LZ, Lu YX, Zhang DS, Zeng ZL, Pan ZZ, et al. Long noncoding RNA XIST expedites metastasis and modulates epithelial-mesenchymal transition in colorectal cancer. Cell Death Dis. 2017;8:e3011.
pubmed: 28837144
pmcid: 5596599
doi: 10.1038/cddis.2017.421
Li Z, Xu Z, Xie Q, Gao W, Xie J, Zhou L. miR-1303 promotes the proliferation of neuroblastoma cell SH-SY5Y by targeting GSK3β and SFRP1. Biomed Pharmacother. 2016;83:508–13.
pubmed: 27434867
doi: 10.1016/j.biopha.2016.07.010
Zhu H, Zheng T, Yu J, Zhou L, Wang L. LncRNA XIST accelerates cervical cancer progression via upregulating Fus through competitively binding with miR-200a. Biomed Pharmacother. 2018;105:789–97.
pubmed: 29909347
doi: 10.1016/j.biopha.2018.05.053
Zheng R, Lin S, Guan L, Yuan H, Liu K, Liu C, et al. Long non-coding RNA XIST inhibited breast cancer cell growth, migration, and invasion via miR-155/CDX1 axis. Biochem Biophys Res Commun. 2018;498:1002–8.
pubmed: 29550489
doi: 10.1016/j.bbrc.2018.03.104
Zhang J, Li WY, Yang Y, Yan LZ, Zhang SY, He J, et al. LncRNA XIST facilitates cell growth, migration and invasion via modulating H3 histone methylation of DKK1 in neuroblastoma. Cell Cycle. 2019;18:1882–92.
pubmed: 31208278
pmcid: 6681787
doi: 10.1080/15384101.2019.1632134
Rathjen FG, Schachner M. Immunocytological and biochemical characterization of a new neuronal cell surface component (L1 antigen) which is involved in cell adhesion. EMBO J. 1984;3:1–10.
pubmed: 6368220
pmcid: 557289
doi: 10.1002/j.1460-2075.1984.tb01753.x
Na’ara S, Amit M, Gil Z. L1CAM induces perineural invasion of pancreas cancer cells by upregulation of metalloproteinase expression. Oncogene. 2019;38:596–608.
pubmed: 30171263
doi: 10.1038/s41388-018-0458-y
Corrado G, Laquintana V, Loria R, Carosi M, de Salvo L, Sperduti I, et al. Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers. J Exp Clin Cancer Res. 2018;37:139.
pubmed: 29980240
pmcid: 6035393
doi: 10.1186/s13046-018-0816-1
Wachowiak R, Krause M, Mayer S, Peukert N, Suttkus A, Müller WC, et al. Increased L1CAM (CD171) levels are associated with glioblastoma and metastatic brain tumors. Medicine (Baltim). 2018;97:e12396.
doi: 10.1097/MD.0000000000012396
Yang H, Zhang X, Zhao Y, Sun G, Zhang J, Gao Y, et al. Downregulation of lncRNA XIST represses tumor growth and boosts radiosensitivity of neuroblastoma via modulation of the miR-375/L1CAM Axis. Neurochem Res. 2020;45:2679–90.
pubmed: 32857295
doi: 10.1007/s11064-020-03117-9
Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008;100:35–83.
pubmed: 18620092
pmcid: 3133732
doi: 10.1016/S0065-230X(08)00002-X
Brandão L, Migdall-Wilson J, Eisenman K, Graham DK. TAM receptors in leukemia: expression, signaling, and therapeutic implications. Crit Rev Oncog. 2011;16:47–63.
pubmed: 22150307
pmcid: 4855299
doi: 10.1615/CritRevOncog.v16.i1-2.60
Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell. 1995;80:661–70.
pubmed: 7867073
doi: 10.1016/0092-8674(95)90520-0
Neubauer A, Fiebeler A, Graham DK, O’Bryan JP, Schmidt CA, Barckow P, et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood. 1994;84:1931–41.
pubmed: 7521695
doi: 10.1182/blood.V84.6.1931.1931
Linger RM, Keating AK, Earp HS, Graham DK. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets. 2010;14:1073–90.
pubmed: 20809868
pmcid: 3342018
doi: 10.1517/14728222.2010.515980
Li Y, Wang X, Bi S, Zhao K, Yu C. Inhibition of Mer and Axl receptor tyrosine kinases leads to increased apoptosis and improved chemosensitivity in human neuroblastoma. Biochem Biophys Res Commun. 2015;457:461–6.
pubmed: 25596315
doi: 10.1016/j.bbrc.2015.01.017
Bi S, Wang C, Li Y, Zhang W, Zhang J, Lv Z, et al. LncRNA-MALAT1-mediated Axl promotes cell invasion and migration in human neuroblastoma. Tumour Biol. 2017;39:1010428317699796.
pubmed: 28468579
doi: 10.1177/1010428317699796
Hu P, Chu J, Wu Y, Sun L, Lv X, Zhu Y, et al. NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2. Oncotarget. 2015;6:32410–25.
pubmed: 26378045
pmcid: 4741702
doi: 10.18632/oncotarget.5609
Koppen A, Ait-Aissa R, Hopman S, Koster J, Haneveld F, Versteeg R, et al. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation. Cancer Lett. 2007;256:218–28.
pubmed: 17643814
doi: 10.1016/j.canlet.2007.06.011
Ke XX, Zhang D, Zhao H, Hu R, Dong Z, Yang R, et al. Phox2B correlates with MYCN and is a prognostic marker for neuroblastoma development. Oncol Lett. 2015;9:2507–14.
pubmed: 26137098
pmcid: 4473365
doi: 10.3892/ol.2015.3088
Wang KP, Bai Y, Wang J, Zhang JZ. Morphine protects SH-SY5Y human neuroblastoma cells against Dickkopf1-induced apoptosis. Mol Med Rep. 2015;11:1174–80.
pubmed: 25370481
doi: 10.3892/mmr.2014.2832
Rawson JB, Sun Z, Dicks E, Daftary D, Parfrey PS, Green RC, et al. Vitamin D intake is negatively associated with promoter methylation of the Wnt antagonist gene DKK1 in a large group of colorectal cancer patients. Nutr Cancer. 2012;64:919–28.
pubmed: 22966878
pmcid: 4323165
doi: 10.1080/01635581.2012.711418
Liang L, He H, Lv R, Zhang M, Huang H, An Z, et al. Preliminary mechanism on the methylation modification of Dkk-1 and Dkk-3 in hepatocellular carcinoma. Tumour Biol. 2015;36:1245–50.
pubmed: 25344678
doi: 10.1007/s13277-014-2750-y
Hattori N, Ushijima T. Compendium of aberrant DNA methylation and histone modifications in cancer. Biochem Biophys Res Commun. 2014;455:3–9.
pubmed: 25194808
doi: 10.1016/j.bbrc.2014.08.140
Han LiC, Chen Y. Targeting EZH2 for cancer therapy: progress and perspective. Curr Protein Pept Sci. 2015;16:559–70.
doi: 10.2174/1389203716666150409100233
Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei JS, et al. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res. 2012;72:315–24.
pubmed: 22068036
doi: 10.1158/0008-5472.CAN-11-0961
Yun CW, Lee SH. The Roles of Autophagy in Cancer. Int J Mol Sci. 2018;19:3466.
pubmed: 30400561
pmcid: 6274804
doi: 10.3390/ijms19113466
Pickard MR, Mourtada-Maarabouni M, Williams GT. Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta. 2013;1832:1613–23.
pubmed: 23676682
doi: 10.1016/j.bbadis.2013.05.005
Mazar J, Rosado A, Shelley J, Marchica J, Westmoreland TJ. The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma. Oncotarget. 2017;8:6589–607.
pubmed: 28035057
doi: 10.18632/oncotarget.14244
Smith CM, Steitz JA. Classification of gas5 as a multi-small-nucleolar-RNA (snoRNA) host gene and a member of the 5’-terminal oligopyrimidine gene family reveals common features of snoRNA host genes. Mol Cell Biol. 1998;18:6897–909.
pubmed: 9819378
pmcid: 109273
doi: 10.1128/MCB.18.12.6897
Renganathan A, Kresoja-Rakic J, Echeverry N, Ziltener G, Vrugt B, Opitz I, et al. GAS5 long non-coding RNA in malignant pleural mesothelioma. Mol Cancer. 2014;13:119.
pubmed: 24885398
pmcid: 4039656
doi: 10.1186/1476-4598-13-119
Pickard MR, Williams GT. Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy. Breast Cancer Res Treat. 2014;145:359–70.
pubmed: 24789445
doi: 10.1007/s10549-014-2974-y
Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene. 2009;28:195–208.
pubmed: 18836484
doi: 10.1038/onc.2008.373
Zhou WY, Cai ZR, Liu J, Wang DS, Ju HQ, Xu RH. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020;19:172.
pubmed: 33317550
pmcid: 7734744
doi: 10.1186/s12943-020-01286-3
Yang T, Zhang Z, Zhang J, Tan T, Yang J, Pan J, et al. The rs2147578 C > G polymorphism in the Inc-LAMC2-1:1 gene is associated with increased neuroblastoma risk in the Henan children. BMC Cancer. 2018;18:948.
pubmed: 30285664
pmcid: 6171233
doi: 10.1186/s12885-018-4847-y
Chen Y, Lian YJ, Ma YQ, Wu CJ, Zheng YK, Xie NC. LncRNA SNHG1 promotes α-synuclein aggregation and toxicity by targeting miR-15b-5p to activate SIAH1 in human neuroblastoma SH-SY5Y cells. Neurotoxicology. 2018;68:212–21.
pubmed: 29217406
doi: 10.1016/j.neuro.2017.12.001
Tang M, Kui L, Lu G, Chen W. Disease-associated circular RNAs: from biology to computational identification. BioMed Res Int. 2020;2020:6798590.
pubmed: 32908906
pmcid: 7450300
doi: 10.1155/2020/6798590
Pan W, Wu A, Yu H, Yu Q, Zheng B, Yang W, et al. NEAT1 negatively regulates cell proliferation and migration of neuroblastoma cells by miR-183-5p/FOXP1 via the ERK/AKT pathway. Cell Transpl. 2020;29:963689720943608.
doi: 10.1177/0963689720943608
Xu F, Wang H, Tian J, Xu H. Down-regulation of ID2-AS1 alleviates the neuronal injury induced by 1-methy1-4-phenylpyridinium in human neuroblastoma cell line SH-SY5Y cells through regulating miR-199a-5p/IFNAR1/JAK2/STAT1 Axis. Neurochem Res. 2021;46:2192–203.
pubmed: 34050453
doi: 10.1007/s11064-021-03356-4
Ge Y, Tan S, Bi J, Rao M, Yu Y, Tian L. SNHG16 knockdown inhibits tumorigenicity of neuroblastoma in children via miR-15b-5p/PRPS1 axis. Neuroreport. 2020;31:1225–35.
pubmed: 33105440
doi: 10.1097/WNR.0000000000001537
Fontemaggi G, Turco C, Esposito G, Di Agostino S. New molecular mechanisms and clinical impact of circRNAs in human cancer. Cancers. 2021;13:3154.
pubmed: 34202482
pmcid: 8268751
doi: 10.3390/cancers13133154
Chi R, Chen X, Liu M, Zhang H, Li F, Fan X, et al. Role of SNHG7-miR-653-5p-STAT2 feedback loop in regulating neuroblastoma progression. J Cell Physiol. 2019;234:13403–12.
pubmed: 30623419
doi: 10.1002/jcp.28017
Bao J, Zhang S, Meng Q, Qin T. SNHG16 silencing inhibits neuroblastoma progression by downregulating HOXA7 via sponging miR-128-3p. Neurochem Res. 2020;45:825–36.
pubmed: 31919621
doi: 10.1007/s11064-020-02955-x
Xu Z, Sun Y, Wang D, Sun H, Liu X. SNHG16 promotes tumorigenesis and cisplatin resistance by regulating miR-338-3p/PLK4 pathway in neuroblastoma cells. Cancer Cell Int. 2020;20:236.
pubmed: 32536824
pmcid: 7291484
doi: 10.1186/s12935-020-01291-y
Avery JT, Zhang R, Boohaker RJ. GLI1: a therapeutic target for cancer. Front Oncol. 2021;11:673154.
pubmed: 34113570
pmcid: 8186314
doi: 10.3389/fonc.2021.673154
Cao D, Yu T, Ou X. MiR-873-5P controls gastric cancer progression by targeting hedgehog-GLI signaling. Pharmazie. 2016;71:603–6.
pubmed: 29441930
Huang XY, Huang ZL, Xu YH, Zheng Q, Chen Z, Song W, et al. Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-100338/miR-141-3p pathway in hepatitis B-related hepatocellular carcinoma. Sci Rep. 2017;7:5428.
pubmed: 28710406
pmcid: 5511135
doi: 10.1038/s41598-017-05432-8
Schiapparelli P, Shahi MH, Enguita-Germán M, Johnsen JI, Kogner P, Lázcoz P, et al. Inhibition of the sonic hedgehog pathway by cyplopamine reduces the CD133+/CD15+ cell compartment and the in vitro tumorigenic capability of neuroblastoma cells. Cancer Lett. 2011;310:222–31.
pubmed: 21803487
doi: 10.1016/j.canlet.2011.07.005
Xu L, Wang X, Wan J, Li T, Gong X, Zhang K, et al. Sonic Hedgehog pathway is essential for neuroblastoma cell proliferation and tumor growth. Mol Cell Biochem. 2012;364:235–41.
pubmed: 22350753
doi: 10.1007/s11010-011-1222-6
Wickström M, Dyberg C, Shimokawa T, Milosevic J, Baryawno N, Fuskevåg OM, et al. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer. 2013;132:1516–24.
pubmed: 22949014
doi: 10.1002/ijc.27820
Diao Y, Rahman MF, Vyatkin Y, Azatyan A, St Laurent G, Kapranov P, et al. Identification of novel GLI1 target genes and regulatory circuits in human cancer cells. Mol Oncol. 2018;12:1718–34.
pubmed: 30098229
pmcid: 6166001
doi: 10.1002/1878-0261.12366
Xu L, Kwon YJ, Frolova N, Steg AD, Yuan K, Johnson MR, et al. Gli1 promotes cell survival and is predictive of a poor outcome in ERalpha-negative breast cancer. Breast Cancer Res Treat. 2010;123:59–71.
pubmed: 19902354
doi: 10.1007/s10549-009-0617-5
Cheng J, Deng R, Wu C, Zhang P, Wu K, Shi L, et al. Inhibition of SALL4 suppresses carcinogenesis of colorectal cancer via regulating Gli1 expression. Int J Clin Exp Pathol. 2015;8:10092–101.
pubmed: 26617716
pmcid: 4637531
Chen G, Goto Y, Sakamoto R, Tanaka K, Matsubara E, Nakamura M, et al. GLI1, a crucial mediator of sonic hedgehog signaling in prostate cancer, functions as a negative modulator for androgen receptor. Biochem Biophys Res Commun. 2011;404:809–15.
pubmed: 21172305
doi: 10.1016/j.bbrc.2010.12.065
Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007;17:165–72.
pubmed: 17196391
doi: 10.1016/j.cub.2006.11.033
Gan H, Liu H, Zhang H, Li Y, Xu X, Xu X, et al. SHh-Gli1 signaling pathway promotes cell survival by mediating baculoviral IAP repeat-containing 3 (BIRC3) gene in pancreatic cancer cells. Tumour Biol. 2016;37:9943–50.
pubmed: 26815504
doi: 10.1007/s13277-016-4898-0
Sun L, Yao Y, Pan G, Zhan S, Shi W, Lu T, et al. Small interfering RNA-mediated knockdown of fatty acid synthase attenuates the proliferation and metastasis of human gastric cancer cells via the mTOR/Gli1 signaling pathway. Oncol Lett. 2018;16:594–602.
pubmed: 29928446
pmcid: 6006441
Wen Y, Gong X, Dong Y, Tang C. Long Non Coding RNA SNHG16 Facilitates Proliferation, Migration, Invasion and Autophagy of Neuroblastoma Cells via Sponging miR-542-3p and Upregulating ATG5 Expression. OncoTargets Ther. 2020;13:263–75.
doi: 10.2147/OTT.S226915
Nayak A, Satapathy SR, Das D, Siddharth S, Tripathi N, Bharatam PV, et al. Nanoquinacrine induced apoptosis in cervical cancer stem cells through the inhibition of hedgehog-GLI1 cascade: Role of GLI-1. Sci Rep. 2016;6:20600.
pubmed: 26846872
pmcid: 4742869
doi: 10.1038/srep20600
Yang J, Yu L, Yan J, Xiao Y, Li W, Xiao J, et al. Circular RNA DGKB Promotes the Progression of Neuroblastoma by Targeting miR-873/GLI1 Axis. Front Oncol. 2020;10:1104.
pubmed: 32793474
pmcid: 7390925
doi: 10.3389/fonc.2020.01104
Wang J, Zuo J, Wang M, Ma X, Gao K, Bai X, et al. Polo‑like kinase 4 promotes tumorigenesis and induces resistance to radiotherapy in glioblastoma. Oncol Rep. 2019;41:2159–67.
pubmed: 30816483
pmcid: 6412581
Liao Z, Zhang H, Fan P, Huang Q, Dong K, Qi Y, et al. High PLK4 expression promotes tumor progression and induces epithelial‑mesenchymal transition by regulating the Wnt/β‑catenin signaling pathway in colorectal cancer. Int J Oncol. 2019;54:479–90.
pubmed: 30570110
doi: 10.3892/ijo.2018.4659
Marina M, Saavedra HI. Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. Front Biosci (Landmark Ed). 2014;19:352–65.
pubmed: 24389189
doi: 10.2741/4212
Zhang N, Liu FL, Ma TS, Zhang ZZJ. LncRNA SNHG1 contributes to tumorigenesis and mechanism by targeting miR-338-3p to regulate PLK4 in human neuroblastoma. Eur Rev Med Pharm Sci. 2019;23:8971–83.
Tian X, Zhou D, Chen L, Tian Y, Zhong B, Cao Y, et al. Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway. Cell Death Dis. 2018;9:54.
pubmed: 29352113
pmcid: 5833556
doi: 10.1038/s41419-017-0088-2
Fang Y, Yao Y, Mao K, Zhong Y, Xu Y. Circ_0132817 facilitates cell proliferation, migration, invasion and glycolysis by regulating the miR-432-5p/NOL4L axis in neuroblastoma. Exp Brain Res. 2021;239:1841–52.
pubmed: 33837793
doi: 10.1007/s00221-021-06091-y
Chen Y, Lin L, Hu X, Li Q, Wu M. Silencing of circular RNA circPDE5A suppresses neuroblastoma progression by targeting the miR-362-5p/NOL4L axis. Int J Neurosci. 2021;133:141–51.
Yang Y, Pan H, Chen J, Zhang Z, Liang M, Feng X. CircKIF2A contributes to cell proliferation, migration, invasion and glycolysis in human neuroblastoma by regulating miR-129-5p/PLK4 axis. Mol Cell Biochem. 2021;476:2513–25.
pubmed: 33630225
doi: 10.1007/s11010-021-04096-3
Liu H, Xue L, Song C, Liu F, Jiang T, Yang X. Overexpression of circular RNA circ_001569 indicates poor prognosis in hepatocellular carcinoma and promotes cell growth and metastasis by sponging miR-411-5p and miR-432-5p. Biochem Biophys Res Commun. 2018;503:2659–65.
pubmed: 30086881
doi: 10.1016/j.bbrc.2018.08.020
Li JB, Liu F, Zhang BP, Bai WK, Cheng W, Zhang YH, et al. LncRNA625 modulates prostate cancer cells proliferation and apoptosis through regulating the Wnt/β-catenin pathway by targeting miR-432. Eur Rev Med Pharm Sci. 2017;21:2586–95.
Li H, Yang F, Hu A, Wang X, Fang E, Chen Y, et al. Therapeutic targeting of circ-CUX1/EWSR1/MAZ axis inhibits glycolysis and neuroblastoma progression. EMBO Mol Med. 2019;11:e10835.
pubmed: 31709724
pmcid: 6895612
doi: 10.15252/emmm.201910835
Mahmoudi E, Kiltschewskij D, Fitzsimmons C, Cairns MJ. Depolarization-associated circRNA regulate neural gene expression and in some cases may function as templates for translation. Cells. 2019;9:25.
pubmed: 31861825
pmcid: 7017197
doi: 10.3390/cells9010025
Yang F, Hu A, Guo Y, Wang J, Li D, Wang X, et al. p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation. Mol Cancer. 2021;20:123.
pubmed: 34579723
pmcid: 8474885
doi: 10.1186/s12943-021-01421-8
Su M, Xiao Y, Ma J, Tang Y, Tian B, Zhang Y, et al. Circular RNAs in Cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers. Mol Cancer. 2019;18:90.
pubmed: 30999909
pmcid: 6471953
doi: 10.1186/s12943-019-1002-6
Bobrie A, Colombo M, Raposo G, Théry C. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic. 2011;12:1659–68.
pubmed: 21645191
doi: 10.1111/j.1600-0854.2011.01225.x
Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9.
pubmed: 17486113
doi: 10.1038/ncb1596
Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373–83.
pubmed: 23420871
pmcid: 3575529
doi: 10.1083/jcb.201211138
Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M, et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 2010;70:1668–78.
pubmed: 20124479
doi: 10.1158/0008-5472.CAN-09-2470
Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012;31:3513–23.
pubmed: 22773185
pmcid: 3433782
doi: 10.1038/emboj.2012.183
Umezu T, Ohyashiki K, Kuroda M, Ohyashiki JH. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene. 2013;32:2747–55.
pubmed: 22797057
doi: 10.1038/onc.2012.295
Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18:883–91.
pubmed: 22635005
pmcid: 3645291
doi: 10.1038/nm.2753
Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012;151:1542–56.
pubmed: 23260141
doi: 10.1016/j.cell.2012.11.024
Kogure T, Lin WL, Yan IK, Braconi C, Patel T. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology. 2011;54:1237–48.
pubmed: 21721029
doi: 10.1002/hep.24504
Kosaka N, Iguchi H, Yoshioka Y, Hagiwara K, Takeshita F, Ochiya T. Competitive interactions of cancer cells and normal cells via secretory microRNAs. J Biol Chem. 2012;287:1397–405.
pubmed: 22123823
doi: 10.1074/jbc.M111.288662
Marimpietri D, Airoldi I, Faini AC, Malavasi F, Morandi F. The role of extracellular vesicles in the progression of human neuroblastoma. Int J Mol Sci. 2021;22:3964.
pubmed: 33921337
pmcid: 8069919
doi: 10.3390/ijms22083964
Vader P, Breakefield XO, Wood MJ. Extracellular vesicles: emerging targets for cancer therapy. Trends Mol Med. 2014;20:385–93.
pubmed: 24703619
pmcid: 4082760
doi: 10.1016/j.molmed.2014.03.002
Xu P, Xu H, Cheng HS, Chan HH, Wang RYL. MicroRNA 876-5p modulates EV-A71 replication through downregulation of host antiviral factors. Virol J. 2020;17:21.
pubmed: 32024541
pmcid: 7003331
doi: 10.1186/s12985-020-1284-8
Kosaka N, Yoshioka Y, Fujita Y, Ochiya T. Versatile roles of extracellular vesicles in cancer. J Clin Invest. 2016;126:1163–72.
pubmed: 26974161
pmcid: 4811151
doi: 10.1172/JCI81130
Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med. 2012;10:134.
pubmed: 22738135
pmcid: 3441244
doi: 10.1186/1479-5876-10-134
Raimondo S, Pucci M, Alessandro R, Fontana S. Extracellular vesicles and tumor-immune escape: biological functions and clinical perspectives. Int J Mol Sci. 2020;21:2286.
pubmed: 32225076
pmcid: 7177226
doi: 10.3390/ijms21072286
EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Disco. 2013;12:347–57.
doi: 10.1038/nrd3978
Kanamori Y, Finotti A. Enzymatic spermine metabolites induce apoptosis associated with increase of p53, caspase-3 and miR-34a in both neuroblastoma cells, SJNKP and the N-Myc-amplified form IMR5. Cells. 2021;10:1950.
pubmed: 34440719
pmcid: 8393918
doi: 10.3390/cells10081950
Peng Z, Yang X, Zhang H, Yin M, Luo Y, Xie C. MiR-29b-3p aggravates NG108-15 cell apoptosis triggered by fluorine combined with aluminum. Ecotoxicol Environ Saf. 2021;224:112658.
pubmed: 34425535
doi: 10.1016/j.ecoenv.2021.112658
Yang L, He K, Yao S, Zhang Y, Shen J. Sevoflurane inhibits neuroblastoma cell proliferation and invasion and induces apoptosis by miR-144-3p/YAP1 axis. Basic Clin Pharmacol Toxicol. 2021;129: 297–307.
Subramanian M, Hyeon SJ, Das T, Suh YS, Kim YK. UBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation. Nat Commun. 2021;12:3291.
Yuan H, Liu F, Ma T, Zeng Z, Zhang N. miR-338-3p inhibits cell growth, invasion, and EMT process in neuroblastoma through targeting MMP-2. Open Life Sci. 2021;16:198–209.
pubmed: 33817311
pmcid: 7968531
doi: 10.1515/biol-2021-0013
Li S, Wang Y, Wang M, Chen L, Chen S, Deng F. et al. microRNA-186 alleviates oxygen-glucose deprivation/reoxygenation-induced injury by directly targeting hypoxia-inducible factor-1α. J Biochem Mol Toxicol. 2021;35:1–11.
Zhu X, Wu T, Chi Y, Ge Y, Jiao Y, Zhu F, et al. MicroRNA-195 suppresses enterovirus A71-induced pyroptosis in human neuroblastoma cells through targeting NLRX1. Virus Res. 2021;292:198245.
pubmed: 33253716
doi: 10.1016/j.virusres.2020.198245
Su H, Xiaohui X, He X, Liu C, Wang G, Zhou C. The miR-455-5p/ERα36 axis regulates mammalian neuronal viability and axonal regeneration. Neurosci Lett. 2020;735:135159.
pubmed: 32574796
doi: 10.1016/j.neulet.2020.135159
Cheng J, Xu L, Deng L, Xue L, Meng Q, Wei F, et al. RNA N(6)-methyladenosine modification is required for miR-98/MYCN axis-mediated inhibition of neuroblastoma progression. Sci Rep. 2020;10:13624.
pubmed: 32788584
pmcid: 7424512
doi: 10.1038/s41598-020-64682-1
Liu Z, Zhang H, Sun L, Zhu K, Lang W. miR-29c-3p increases cell viability and suppresses apoptosis by regulating the TNFAIP1/NF-κB signaling pathway via TNFAIP1 in Aβ-treated neuroblastoma cells. Neurochem Res. 2020;45:2375–84.
pubmed: 32712875
doi: 10.1007/s11064-020-03096-x
Ma XL, Zhang XJ, Du Q, Zhang XN, Zhang SY, Zhao HF. microRNA-146b promotes neuroblastoma cell growth through targeting NUMB. Exp Therapeutic Med. 2020;19:3531–6.
Zhao J, Zhou K, Ma L, Zhang H. MicroRNA-145 overexpression inhibits neuroblastoma tumorigenesis in vitro and in vivo. Bioengineered. 2020; 11:219–28.
Wang J, Zhang X, Yao H, Le Y, Zhou W, Li J, et al. MiR-490-5p functions as tumor suppressor in childhood neuroblastoma by targeting MYEOV. Hum Cell. 2020;33:261–71.
pubmed: 31894478
doi: 10.1007/s13577-019-00302-z
Mao F, Zhang J, Cheng X, Xu Q. miR-149 inhibits cell proliferation and enhances chemosensitivity by targeting CDC42 and BCL2 in neuroblastoma. Cancer Cell Int. 2019;19:357.
pubmed: 31889909
pmcid: 6935209
doi: 10.1186/s12935-019-1082-9
Li J, Ma L. MiR-142-3p attenuates oxygen glucose deprivation/reoxygenation-induced injury by targeting FBXO3 in human neuroblastoma SH-SY5Y Cells. World Neurosurg. 2020;136:e149–e157.
pubmed: 31863884
doi: 10.1016/j.wneu.2019.12.064
Yang J, Shao X, Wang L, Xu H, Sun Y, Jiang J, et al. Angelica polysaccharide exhibits antitumor effect in neuroblastoma cell line SH-SY5Y by up-regulation of miR-205. Biofactors. 2019;49:201.
Wu Q, Shang Y, Shen T, Liu F, Xu Y, Wang H. Neuroprotection of miR-214 against isoflurane-induced neurotoxicity involves the PTEN/PI3K/Akt pathway in human neuroblastoma cell line SH-SY5Y. Arch Biochem Biophys. 2019;678:108181.
pubmed: 31704096
doi: 10.1016/j.abb.2019.108181
Ye W, Liang F, Ying C, Zhang M, Feng D, Jiang X. Downregulation of microRNA-3934-5p induces apoptosis and inhibits the proliferation of neuroblastoma cells by targeting TP53INP1. Exp. Therapeutic Med. 2019;18:3729–36.
Chava S, Reynolds CP, Pathania AS, Gorantla S, Poluektova LY, Coulter DW, et al. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. Mol Oncol. 2020; 14:180–96.
Kosti A, Du L, Shivram H, Qiao M, Burns S, Garcia JG, et al. ELF4 Is a Target of miR-124 and promotes neuroblastoma proliferation and undifferentiated state. Mol Cancer Res. 2020;18:68–78.
Yuan XL, Wen FQ, Chen XW, Jiang XP, Liu SX. miR-373 promotes neuroblastoma cell proliferation, migration, and invasion by targeting SRCIN1. OncoTargets Ther. 2019;12:4927–36.
doi: 10.2147/OTT.S205582
Liu G, Xu Z, Hao D. MicroRNA‑451 inhibits neuroblastoma proliferation, invasion and migration by targeting macrophage migration inhibitory factor. Mol Med Rep. 2016;13:2253–60.
pubmed: 26783235
doi: 10.3892/mmr.2016.4770
Yu Y, Zhang J, Jin Y, Yang Y, Shi J, Chen F, et al. MiR-20a-5p suppresses tumor proliferation by targeting autophagy-related gene 7 in neuroblastoma. Cancer Cell Int. 2018;18:5.
pubmed: 29311760
pmcid: 5755308
doi: 10.1186/s12935-017-0499-2
Zhao Z, Partridge V, Sousares M, Shelton SD, Holland CL, Pertsemlidis A, et al. microRNA-2110 functions as an onco-suppressor in neuroblastoma by directly targeting Tsukushi. PLoS ONE. 2018;13:e0208777.
Wang Z, Yao W, Li K, Zheng N, Zheng C, Zhao X, et al. Reduction of miR-21 induces SK-N-SH cell apoptosis and inhibits proliferation via PTEN/PDCD4. Oncol Lett. 2017;13:4727–33.
pubmed: 28599474
pmcid: 5452970
doi: 10.3892/ol.2017.6052
Wang Z, Lei H, Sun Q. MicroRNA-141 and its associated gene FUS modulate proliferation, migration and cisplatin chemosensitivity in neuroblastoma cell lines. Oncol Rep. 2016;35:2943–51.
pubmed: 26936280
pmcid: 4811401
doi: 10.3892/or.2016.4640
Althoff K, Beckers A, Odersky A, Mestdagh P, Köster J, Bray IM, et al. MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. Int J Cancer. 2013;133:1064–73.
pubmed: 23400681
doi: 10.1002/ijc.28091
Gao SL, Wang LZ, Liu HY, Liu DL, Xie LM, Zhang ZW. miR-200a inhibits tumor proliferation by targeting AP-2γ in neuroblastoma cells. Asian Pac J Cancer Prev. 2014;15:4671–6.
pubmed: 24969902
doi: 10.7314/APJCP.2014.15.11.4671
Zhu K, Su Y, Xu B, Wang Z, Sun H, Wang L, et al. MicroRNA-186-5p represses neuroblastoma cell growth via downregulation of Eg5. Am J Transl Res. 2019;11:2245–56.
pubmed: 31105832
pmcid: 6511750
Chen S, Jin L, Nie S, Han L, Lu N, Zhou Y. miR-205 inhibits neuroblastoma growth by targeting cAMP-responsive element-binding protein 1. Oncol Res. 2018;26:445–55.
pubmed: 28653600
pmcid: 7844742
doi: 10.3727/096504017X14974834436195
Harvey H, Piskareva O, Creevey L, Alcock LC, Buckley PG, O’Sullivan MJ, et al. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. Int J Cancer. 2015;136:1579–88.
pubmed: 25137037
doi: 10.1002/ijc.29144
Cao XY, Sun ZY, Zhang LJ, Chen MK, Yuan B. microRNA-144-3p suppresses human neuroblastoma cell proliferation by targeting HOXA7. Eur Rev Med Pharm Sci. 2019;23:716–23.
Soriano A, París-Coderch L, Jubierre L, Martínez A, Zhou X, Piskareva O, et al. MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes. Oncotarget. 2016;7:9271–87.
pubmed: 26824183
pmcid: 4891039
doi: 10.18632/oncotarget.7005
De Brouwer S, Mestdagh P, Lambertz I, Pattyn F, De Paepe A, Westermann F, et al. Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma. Int J Cancer. 2012;130:2591–8.
pubmed: 21796614
doi: 10.1002/ijc.26295
Qu H, Zheng L, Song H, Jiao W, Li D, Fang E, et al. microRNA-558 facilitates the expression of hypoxia-inducible factor 2 alpha through binding to 5’-untranslated region in neuroblastoma. Oncotarget. 2016;7:40657–73.
pubmed: 27276678
pmcid: 5130034
doi: 10.18632/oncotarget.9813
Regis S, Caliendo F, Dondero A, Casu B, Romano F, Loiacono F, et al. TGF-β1 downregulates the expression of CX(3)CR1 by inducing miR-27a-5p in primary human NK cells. Front Immunol. 2017;8:868.
pubmed: 28791023
pmcid: 5524732
doi: 10.3389/fimmu.2017.00868
Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprüssel A, et al. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene. 2015;34:3357–68.
pubmed: 25174395
doi: 10.1038/onc.2014.269
Xin C, Buhe B, Hongting L, Chuanmin Y, Xiwei H, Hong Z, et al. MicroRNA-15a promotes neuroblastoma migration by targeting reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and regulating matrix metalloproteinase-9 expression. FEBS J. 2013;280:855–66.
pubmed: 23176145
Das S, Foley N, Bryan K, Watters KM, Bray I, Murphy DM, et al. MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Cancer Res. 2010;70:7874–81.
pubmed: 20841484
pmcid: 2955783
doi: 10.1158/0008-5472.CAN-10-1534
Zhao H, Zhang C, Hou G, Song J. MicroRNA-H4-5p encoded by HSV-1 latency-associated transcript promotes cell proliferation, invasion and cell cycle progression via p16-mediated PI3K-Akt signaling pathway in SHSY5Y cells. Int J Clin Exp Med. 2015;8:7526–34.
pubmed: 26221296
pmcid: 4509241
Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM, et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res. 2008;6:735–42.
pubmed: 18505919
pmcid: 3760152
doi: 10.1158/1541-7786.MCR-07-2102
Ren X, Bai X, Zhang X, Li Z, Tang L, Zhao X, et al. Quantitative nuclear proteomics identifies that miR-137-mediated EZH2 reduction regulates resveratrol-induced apoptosis of neuroblastoma cells. Mol Cell Proteom. 2015;14:316–28.
doi: 10.1074/mcp.M114.041905
Lodrini M, Poschmann G, Schmidt V, Wünschel J, Dreidax D, Witt O, et al. Minichromosome maintenance complex is a critical node in the miR-183 signaling network of MYCN-amplified neuroblastoma cells. J Proteome Res. 2016;15:2178–86.
pubmed: 27239679
doi: 10.1021/acs.jproteome.6b00134
Zhang H, Qi M, Li S, Qi T, Mei H, Huang K, et al. microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Therapeutics. 2012;11:1454–66.
doi: 10.1158/1535-7163.MCT-12-0001
Wu K, Yang L, Chen J, Zhao H, Wang J, Xu S, et al. miR-362-5p inhibits proliferation and migration of neuroblastoma cells by targeting phosphatidylinositol 3-kinase-C2β. FEBS Lett. 2015;589:1911–9.
pubmed: 26073258
doi: 10.1016/j.febslet.2015.05.056
Fabbri E, Montagner G, Bianchi N, Finotti A, Borgatti M, Lampronti I, et al. MicroRNA miR-93-5p regulates expression of IL-8 and VEGF in neuroblastoma SK-N-AS cells. Oncol Rep. 2016;35:2866–72.
pubmed: 26986724
doi: 10.3892/or.2016.4676
Lodrini M, Oehme I, Schroeder C, Milde T, Schier MC, Kopp-Schneider A, et al. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res. 2013;41:6018–33.
pubmed: 23625969
pmcid: 3695529
doi: 10.1093/nar/gkt346
Soriano A, Masanas M, Boloix A, Masiá N, París-Coderch L, Piskareva O, et al. Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma. Cell Mol Life Sci. 2019;76:2231–43.
pubmed: 30770954
pmcid: 6502783
doi: 10.1007/s00018-019-03041-4
Di Paolo D, Pastorino F, Brignole C, Corrias MV, Emionite L, Cilli M, et al. Combined replenishment of miR-34a and let-7b by targeted nanoparticles inhibits tumor growth in neuroblastoma preclinical models. Small. 2020;16:e1906426.
Cheng M, Liu L, Lao Y, Liao W, Liao M, Luo X, et al. MicroRNA-181a suppresses parkin-mediated mitophagy and sensitizes neuroblastoma cells to mitochondrial uncoupler-induced apoptosis. Oncotarget. 2016;7:42274.
pubmed: 27281615
pmcid: 5173134
doi: 10.18632/oncotarget.9786
Yang J, Shao X, Jiang J, Sun Y, Wang L, Sun L. Angelica sinensis polysaccharide inhibits proliferation, migration, and invasion by downregulating microRNA‐675 in human neuroblastoma cell line SH‐SY5Y. Cell Biol Int. 2018;42:867–76.
pubmed: 29465760
doi: 10.1002/cbin.10954
Patil KS, Basak I, Pal R, Ho HP, Alves G, Chang EJ, et al. A proteomics approach to investigate miR-153-3p and miR-205-5p targets in neuroblastoma cells. PLoS ONE. 2015;10:e0143969.
pubmed: 26633009
pmcid: 4669106
doi: 10.1371/journal.pone.0143969
He X-Y, Tan Z-L, Mou Q, Liu F-J, Liu S, Yu C-W, et al. MicroRNA-221 enhances MYCN via targeting nemo-like kinase and functions as an oncogene related to poor prognosis in neuroblastoma. Clin Cancer Res. 2017;23:2905–18.
pubmed: 28003306
doi: 10.1158/1078-0432.CCR-16-1591
Tivnan A, Tracey L, Buckley PG, Alcock LC, Davidoff AM, Stallings RL. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer. 2011;11:1–11.
doi: 10.1186/1471-2407-11-33
Zhao D, Tian Y, Li P, Wang L, Xiao A, Zhang M, et al. MicroRNA-203 inhibits the malignant progression of neuroblastoma by targeting Sam68. Mol Med Rep. 2015;12:5554–60.
pubmed: 26136151
doi: 10.3892/mmr.2015.4013
Xia H-L, Lv Y, Xu C-W, Fu M-C, Zhang T, Yan X-M, et al. MiR-513c suppresses neuroblastoma cell migration, invasion, and proliferation through direct targeting glutaminase (GLS). Cancer Biomark. 2017;20:589–96.
pubmed: 28800318
doi: 10.3233/CBM-170577
Samaraweera L, Grandinetti KB, Huang R, Spengler BA, Ross RA. MicroRNAs define distinct human neuroblastoma cell phenotypes and regulate their differentiation and tumorigenicity. BMC Cancer. 2014;14:309.
pubmed: 24885481
pmcid: 4038381
doi: 10.1186/1471-2407-14-309
Xu Y, Chen X, Lin L, Chen H, Yu S, Li D. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification. Biochimie. 2017;139:1–8.
pubmed: 28456710
doi: 10.1016/j.biochi.2017.04.011
Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, Khan AR, et al. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer. 2013;12:1–12.
doi: 10.1186/1476-4598-12-23
Mundalil Vasu M, Anitha A, Takahashi T, Thanseem I, Iwata K, Asakawa T, et al. Fluoxetine increases the expression of miR-572 and miR-663a in human neuroblastoma cell lines. PLoS ONE. 2016;11:e0164425.
pubmed: 27716787
pmcid: 5055328
doi: 10.1371/journal.pone.0164425
Chen Y, Tsai Y-H, Tseng S-H. Inhibition of cyclin-dependent kinase 1–induced cell death in neuroblastoma cells through the microRNA-34a–MYCN–survivin pathway. Surgery. 2013;153:4–16.
pubmed: 22703967
doi: 10.1016/j.surg.2012.03.030
Li Z, Chen H. miR-34a inhibits proliferation, migration and invasion of paediatric neuroblastoma cells via targeting HNF4α. Artif Cells Nanomed Biotechnol. 2019;47:3072–8.
pubmed: 31343368
doi: 10.1080/21691401.2019.1637886
Yang H, Li Q, Zhao W, Yuan D, Zhao H, Zhou Y. miR-329 suppresses the growth and motility of neuroblastoma by targeting KDM1A. FEBS Lett. 2014;588:192–7.
pubmed: 24316513
doi: 10.1016/j.febslet.2013.11.036
Qiao J, Lee S, Paul P, Theiss L, Tiao J, Qiao L, et al. miR-335 and miR-363 regulation of neuroblastoma tumorigenesis and metastasis. Surgery. 2013;154:226–33.
pubmed: 23806264
doi: 10.1016/j.surg.2013.04.005
Chen X, Pan M, Han L, Lu H, Hao X, Dong Q. miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett. 2013;587:3729–37.
pubmed: 24140344
doi: 10.1016/j.febslet.2013.09.044
Wang X, Li J, Xu X, Zheng J, Li Q. miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10. Biomed Pharmacother. 2018;103:1312–8.
pubmed: 29864913
doi: 10.1016/j.biopha.2018.04.153
Takwi AA, Wang Y-M, Wu J, Michaelis M, Cinatl J, Chen T. miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. Oncogene. 2014;33:3717–29.
pubmed: 23934188
doi: 10.1038/onc.2013.330
Evangelisti C, Florian MC, Massimi I, Dominici C, Giannini G, Galardi S, et al. MiR‐128 up‐regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J. 2009;23:4276–87.
pubmed: 19713529
doi: 10.1096/fj.09-134965
Cai Z, Zheng F, Ding Y, Zhan Y, Gong R, Li J, et al. Nrf2-regulated miR-380-3p blocks the translation of Sp3 protein and its mediation of paraquat-induced toxicity in mouse neuroblastoma N2a cells. Toxicological Sci. 2019;171:515–29.
doi: 10.1093/toxsci/kfz162
Chen H, Shalom-Feuerstein R, Riley J, Zhang S-D, Tucci P, Agostini M, et al. miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro. Biochem Biophys Res Commun. 2010;394:921–7.
pubmed: 20230785
doi: 10.1016/j.bbrc.2010.03.076
Li Y, Li W, Zhang JG, Li HY, Li YM. Downregulation of tumor suppressor menin by miR-421 promotes proliferation and migration of neuroblastoma. Tumour Biol. 2014;35:10011–7.
pubmed: 25012242
doi: 10.1007/s13277-014-1921-1
Zhang H, Liu T, Yi S, Gu L, Zhou M. Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation. Mol Oncol. 2015;9:1301–11.
pubmed: 25864587
pmcid: 4523463
doi: 10.1016/j.molonc.2015.03.005
Buechner J, Tømte E, Haug B, Henriksen J, Løkke C, Flaegstad T, et al. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer. 2011;105:296–303.
pubmed: 21654684
pmcid: 3142803
doi: 10.1038/bjc.2011.220
Feinberg-Gorenshtein G, Guedj A, Shichrur K, Jeison M, Luria D, Kodman Y, et al. MiR-192 directly binds and regulates Dicer1 expression in neuroblastoma. PLoS ONE. 2013;8:e78713.
pubmed: 24223844
pmcid: 3815303
doi: 10.1371/journal.pone.0078713
Xu L-J, Jiang T, Zhao W, Han J-F, Liu J, Deng Y-Q, et al. Parallel mRNA and microRNA profiling of HEV71-infected human neuroblastoma cells reveal the up-regulation of miR-1246 in association with DLG3 repression. PLoS ONE. 2014;9:e95272.
pubmed: 24739954
pmcid: 3989279
doi: 10.1371/journal.pone.0095272
Lee J-J, Drakaki A, Iliopoulos D, Struhl K. MiR-27b targets PPAR γ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene. 2012;31:3818–25.
pubmed: 22120719
doi: 10.1038/onc.2011.543
Chakrabarti M, Ai W, Banik NL, Ray SK. Overexpression of miR-7-1 increases efficacy of green tea polyphenols for induction of apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-DZ cells. Neurochem Res. 2013;38:420–32.
pubmed: 23192662
doi: 10.1007/s11064-012-0936-5
Guidi M, Muiños-Gimeno M, Kagerbauer B, Martí E, Estivill X, Espinosa-Parrilla Y. Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells. BMC Mol Biol. 2010;11:1–17.
doi: 10.1186/1471-2199-11-95
Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med. 2010;16:1134–40.
pubmed: 20871609
pmcid: 3019350
doi: 10.1038/nm.2227
Huang T-C, Chang H-Y, Chen C-Y, Wu P-Y, Lee H, Liao Y-F, et al. Silencing of miR‐124 induces neuroblastoma SK‐N‐SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR. FEBS Lett. 2011;585:3582–6.
pubmed: 22024478
doi: 10.1016/j.febslet.2011.10.025
Jia J, Zhang D, Zhang J, Yang L, Zhao G, Yang H, et al. Long non-coding RNA SNHG7 promotes neuroblastoma progression through sponging miR-323a-5p and miR-342-5p. Biomed Pharmacother. 2020;128:110293.
pubmed: 32534305
doi: 10.1016/j.biopha.2020.110293
Nie L, Li C, Zhao T, Wang Y, Liu J. LncRNA double homeobox A pseudogene 8 (DUXAP8) facilitates the progression of neuroblastoma and activates Wnt/β-catenin pathway via microRNA-29/nucleolar protein 4 like (NOL4L) axis. Brain Res. 2020;1746:146947.
pubmed: 32522628
doi: 10.1016/j.brainres.2020.146947
Yang B, Ye X, Wang J, Xia S. Long noncoding RNA nuclear-enriched abundant transcript 1 regulates proliferation and apoptosis of neuroblastoma cells treated by cisplatin by targeting miR-326 through Janus kinase/signal transducer and activator of transcription 3 pathway. Neuroreport. 2020;31:1189–98.
pubmed: 33044324
doi: 10.1097/WNR.0000000000001538
Liu L, Zhao H, He HH, Huang J, Xu YY, Li XL, et al. Long non-coding RNA NR2F1-AS1 promoted neuroblastoma progression through miR-493-5p/TRIM2 axis. Eur Rev Med Pharm Sci. 2020;24:12748–56.
Jia P, Wei E, Liu H, Wu T, Wang H. Silencing of long non-coding RNA DLX6-AS1 weakens neuroblastoma progression by the miR-513c-5p/PLK4 axis. IUBMB Life. 2020;72:2627–36.
O’Brien EM, Selfe JL, Martins AS, Walters ZS, Shipley JM. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells. BMC Cancer. 2018;18:217.
Wang H, Liao S, Li H, Chen Y, Yu J. Long non-coding RNA TUG1 sponges Mir-145a-5p to regulate microglial polarization after oxygen-glucose deprivation. Front Mol Neurosci. 2019;12:215.
pubmed: 31551710
pmcid: 6748346
doi: 10.3389/fnmol.2019.00215
Ding XM, Zhao LJ, Qiao HY, Wu SL, Wang XH. Long non-coding RNA-p21 regulates MPP(+)-induced neuronal injury by targeting miR-625 and derepressing TRPM2 in SH-SY5Y cells. Chem Biol Interact. 2019;307:73–81.
pubmed: 31004593
doi: 10.1016/j.cbi.2019.04.017
Deng D, Yang S, Wang X. Long non-coding RNA SNHG16 regulates cell behaviors through miR-542-3p/HNF4α axis via RAS/RAF/MEK/ERK signaling pathway in pediatric neuroblastoma cells. Biosci Rep. 2020;40:BSR20200723.
pubmed: 32412051
pmcid: 7251324
doi: 10.1042/BSR20200723
Li J, Zhuang C, Liu Y, Chen M, Chen Y, Chen Z, et al. Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer. J Exp Clin Cancer Res. 2016;35:99.
pubmed: 27328915
pmcid: 4915162
doi: 10.1186/s13046-016-0372-5
Vance KW, Sansom SN, Lee S, Chalei V, Kong L, Cooper SE, et al. The long non-coding RNA Paupar regulates the expression of both local and distal genes. EMBO J. 2014;33:296–311.
pubmed: 24488179
pmcid: 3983687
doi: 10.1002/embj.201386225
Yang H, Guo JF, Zhang ML, Li AM. LncRNA SNHG4 promotes neuroblastoma proliferation, migration, and invasion by sponging miR-377-3p. Neoplasma. 2020;67:1054–62.
pubmed: 32614236
doi: 10.4149/neo_2020_191023N1081
Chen L, Feng P, Zhu X, He S, Duan J, Zhou D. Long non-coding RNA Malat1 promotes neurite outgrowth through activation of ERK/MAPK signalling pathway in N2a cells. J Cell Mol Med. 2016;20:2102–10.
pubmed: 27374227
pmcid: 5082393
doi: 10.1111/jcmm.12904
Chalei V, Sansom SN, Kong L, Lee S, Montiel JF, Vance KW, et al. The long non-coding RNA Dali is an epigenetic regulator of neural differentiation. eLife. 2014;3:e04530.
pubmed: 25415054
pmcid: 4383022
doi: 10.7554/eLife.04530
Pan J, Lin H, Yang T, Yang J. lncRNA-uc003opf.1 rs11752942 A>G polymorphism decreases neuroblastoma risk in Chinese children. Cell Cycle. 2020;19:2367–72.
Yu Z, Zhang J, Han J. Silencing CASC11 curbs neonatal neuroblastoma progression through modulating microRNA-676-3p/nucleolar protein 4 like (NOL4L) axis. Pediatr Res. 2020;87:662–8.
pubmed: 31645055
doi: 10.1038/s41390-019-0625-z
Wang B, Xu L, Zhang J, Cheng X, Xu Q, Wang J, et al. LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p. Biomed Pharmacother. 2020;129:110268.
pubmed: 32563146
doi: 10.1016/j.biopha.2020.110268
Yan Y, Chen L, Zhou J, Xie L. SNHG12 inhibits oxygen‑glucose deprivation‑induced neuronal apoptosis via the miR‑181a‑5p/NEGR1 axis. Mol Med Rep. 2020;22:3886–94.
pubmed: 33000228
pmcid: 7533499
Hu Y, Sun H, Hu J, Zhang X. LncRNA DLX6-AS1 promotes the progression of neuroblastoma by activating STAT2 via targeting miR-506-3p. Cancer Manag Res. 2020;12:7451–63.
pubmed: 32904436
pmcid: 7455600
doi: 10.2147/CMAR.S252521
Zhou S, Zhang D, Guo J, Chen Z, Chen Y, Zhang J. Deficiency of NEAT1 prevented MPP(+)-induced inflammatory response, oxidative stress and apoptosis in dopaminergic SK-N-SH neuroblastoma cells via miR-1277-5p/ARHGAP26 axis. Brain Res. 2021;1750:147156.
pubmed: 33069733
doi: 10.1016/j.brainres.2020.147156
Ding H, Luo Y, Hu K, Liu P, Xiong M. Linc00467 promotes lung adenocarcinoma proliferation via sponging miR-20b-5p to activate CCND1 expression. OncoTargets Ther. 2019;12:6733–43.
doi: 10.2147/OTT.S207748
Tang W, Dong K, Li K, Dong R, Zheng S. MEG3, HCN3 and linc01105 influence the proliferation and apoptosis of neuroblastoma cells via the HIF-1α and p53 pathways. Sci Rep. 2016;6:36268.
pubmed: 27824082
pmcid: 5099956
doi: 10.1038/srep36268
Zhou X, Lu H, Li F, Han L, Zhang H, Jiang Z, et al. LncRNA cancer susceptibility candidate (CASC7) upregulates phosphatase and tensin homolog by downregulating miR-10a to inhibit neuroblastoma cell proliferation. Neuroreport. 2020;31:381–6.
pubmed: 32101951
doi: 10.1097/WNR.0000000000001411
Pan J, Zhang D, Zhang J, Qin P, Wang J. LncRNA RMRP silence curbs neonatal neuroblastoma progression by regulating microRNA-206/tachykinin-1 receptor axis via inactivating extracellular signal-regulated kinases. Cancer Biol Ther. 2019;20:653–65.
pubmed: 30582709
doi: 10.1080/15384047.2018.1550568
Xie SP, Zhou F, Li J, Duan SJ. NEAT1 regulates MPP(+)-induced neuronal injury by targeting miR-124 in neuroblastoma cells. Neurosci Lett. 2019;708:134340.
pubmed: 31228597
doi: 10.1016/j.neulet.2019.134340
Nan A, Chen L, Zhang N, Liu Z, Yang T, Wang Z, et al. A novel regulatory network among LncRpa, CircRar1, MiR-671 and apoptotic genes promotes lead-induced neuronal cell apoptosis. Arch Toxicol. 2017;91:1671–84.
pubmed: 27604105
doi: 10.1007/s00204-016-1837-1
Mi J, Han Y, Zhang J, Hao X, Xing M, Shang C. Long noncoding RNA LINC01410 promotes the tumorigenesis of neuroblastoma cells by sponging microRNA-506-3p and modulating WEE1. Cancer Med. 2020;9:8133–43.
Gu F, Ji D, Ni H, Chen D. SRY-box 21 antisense RNA 1 knockdown diminishes amyloid beta(25-35)-induced neuronal damage by miR-132/PI3K/AKT pathway. Neurochem Res. 2021;46:2376–86.
pubmed: 34146195
doi: 10.1007/s11064-021-03373-3
Chen Y, Yang F, Fang E, Xiao W, Mei H, Li H, et al. Circular RNA circAGO2 drives cancer progression through facilitating HuR-repressed functions of AGO2-miRNA complexes. Cell Death Differ. 2019;26:1346–64.
pubmed: 30341421
doi: 10.1038/s41418-018-0220-6
Zhang X, Zhang J, Liu Q, Zhao Y, Zhang W, Yang H. Circ-CUX1 accelerates the progression of neuroblastoma via miR-16-5p/DMRT2 axis. Neurochem Res. 2020;45:2840–55.
pubmed: 33000435
doi: 10.1007/s11064-020-03132-w
Wang Y, Niu Q, Dai J, Shi H, Zhang J. circCUX1 promotes neuroblastoma progression and glycolysis by regulating the miR-338-3p/PHF20 axis. Gen Physiol Biophys. 2021;40:17–29.
pubmed: 33655888
doi: 10.4149/gpb_2020041
Lin Q, Chen J, Zheng X, Zhang Y, Tao X, Ye J. Circular RNA Circ_ANKMY2 regulates temporal lobe epilepsy progression via the miR-106b-5p/FOXP1 Axis. Neurochem Res. 2020;45:3034–44.
pubmed: 33095438
doi: 10.1007/s11064-020-03151-7
Chen W, Hao X, Yang B, Zhang Y, Sun L, Hua Y, et al. MYCN‑amplified neuroblastoma cell‑derived exosomal miR‑17‑5p promotes proliferation and migration of non‑MYCN amplified cells. Mol Med Rep. 2021;23:245.
pubmed: 33537818
pmcid: 7893779
doi: 10.3892/mmr.2021.11884
Sharif S, Ghahremani MH, Soleimani M. Differentiation induction and proliferation inhibition by a cell-free approach for delivery of exogenous mirnas to neuroblastoma cells using mesenchymal. Stem Cells Cell J. 2021;22:556–64.
pubmed: 32347050
Colletti M, Tomao L, Galardi A, Paolini A, Di Paolo V, De Stefanis C, et al. Neuroblastoma-secreted exosomes carrying miR-375 promote osteogenic differentiation of bone-marrow mesenchymal stromal cells. J Extracell Vesicles. 2020;9:1774144.
Morini M, Cangelosi D, Segalerba D, Marimpietri D, Raggi F, Castellano A, et al. Exosomal microRNAs from longitudinal liquid biopsies for the prediction of response to induction chemotherapy in high-risk neuroblastoma patients: a proof of concept SIOPEN study. Cancers. 2019;11:1476.
pubmed: 31575060
pmcid: 6826693
doi: 10.3390/cancers11101476
Ma J, Xu M, Yin M, Hong J, Chen H, Gao Y, et al. Exosomal hsa-miR199a-3p promotes proliferation and migration in neuroblastoma. Front Oncol. 2019;9:459.
pubmed: 31249805
pmcid: 6582313
doi: 10.3389/fonc.2019.00459
Neviani P, Wise PM, Murtadha M, Liu CW, Wu CH, Jong AY, et al. Natural killer-derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms. Cancer Res. 2019;79:1151–64.
Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst. 2015;107:djv135.
pubmed: 25972604
pmcid: 4651042
doi: 10.1093/jnci/djv135
Haug BH, Hald ØH, Utnes P, Roth SA, Løkke C, Flægstad T, et al. Exosome-like extracellular vesicles from MYCN-amplified neuroblastoma cells contain oncogenic miRNAs. Anticancer Res. 2015;35:2521–30.
pubmed: 25964525
Shi L, Xiao R, Wang M, Zhang M, Weng N, Zhao X, et al. MicroRNA‑342‑3p suppresses proliferation and invasion of nasopharyngeal carcinoma cells by directly targeting Cdc42. Oncol Rep. 2018;40:2750–7.
pubmed: 30106159
Liu Z, Wang W, Jiang J, Bao E, Xu D, Zeng Y, et al. Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. PLoS ONE. 2013;8:e73991.
pubmed: 24069260
pmcid: 3775789
doi: 10.1371/journal.pone.0073991